1-(4-chlorophenyl)-3-(4-sulfamoylphenyl)urea profile

1-(4-chlorophenyl)-3-(4-sulfamoylphenyl)urea is a compound that is commonly known as **glibenclamide** or **glyburide**.

**Why it's important for research:**

* **Diabetes treatment:** Glibenclamide is a **sulfonylurea drug** widely used in the treatment of **type 2 diabetes**. It works by stimulating the release of insulin from the pancreas, helping regulate blood sugar levels.
* **Research tool:** It is used as a research tool to study the **mechanisms of insulin secretion** and the **role of the sulfonylurea receptor (SUR)** in various cellular processes.
* **Potential for other applications:** Research is ongoing to explore its potential in other areas, such as **cancer therapy** and **neuroprotection**.

**Here's a breakdown of its key features and importance:**

* **Structure:** Glibenclamide is a complex molecule with a urea linker connecting two aromatic rings. One ring carries a chlorine atom, and the other a sulfamoyl group.
* **Mechanism of action:** It binds to the SUR1 subunit of the ATP-sensitive potassium channel (KATP) in pancreatic beta cells. This binding leads to the closure of the channel, which triggers the release of insulin.
* **Therapeutic benefits:** Glibenclamide helps improve glycemic control in patients with type 2 diabetes by increasing insulin secretion. It is an effective medication for managing the disease, although its use may be limited in some cases.
* **Research applications:** As a potent inhibitor of KATP channels, glibenclamide is used extensively in research to:
* **Investigate the role of KATP channels in various cellular processes.**
* **Study the mechanism of insulin secretion.**
* **Develop new drugs that target KATP channels for various medical conditions.**

**In conclusion,** glibenclamide is a significant compound for both clinical and research purposes. Its use in the treatment of type 2 diabetes and its role as a research tool for understanding cellular mechanisms make it a valuable asset in the pharmaceutical and scientific communities.

ID Source	ID
PubMed CID	730672
CHEMBL ID	1446150
CHEBI ID	112239
SCHEMBL ID	671549

Synonym
smr000230984
MLS000704335 ,
OPREA1_331972
OPREA1_659254
4-{[(4-chloroanilino)carbonyl]amino}benzenesulfonamide
AI-204/31750036 ,
STK019184
4-{[(4-chlorophenyl)carbamoyl]amino}benzenesulfonamide
CHEBI:112239
AKOS000489358
1-(4-chlorophenyl)-3-(4-sulfamoylphenyl)urea
CHEMBL1446150
4-{([(4'-chlorophenyl)amino]carbonylamino)}benzenesulfonamide
173550-69-1
SCHEMBL671549
HACQCGHVZICZSC-UHFFFAOYSA-N
bdbm56662
cid_730672
Q27192341
DTXSID10352643

Class	Description
sulfonamide	An amide of a sulfonic acid RS(=O)2NR'2.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
glp-1 receptor, partial	Homo sapiens (human)	Potency	7.0795	0.0184	6.8060	14.1254	AID624417
ATAD5 protein, partial	Homo sapiens (human)	Potency	10.3183	0.0041	10.8903	31.5287	AID504467
TDP1 protein	Homo sapiens (human)	Potency	16.3601	0.0008	11.3822	44.6684	AID686978
nuclear factor erythroid 2-related factor 2 isoform 2	Homo sapiens (human)	Potency	10.3225	0.0041	9.9848	25.9290	AID504444
nuclear receptor ROR-gamma isoform 1	Mus musculus (house mouse)	Potency	18.8541	0.0079	8.2332	1,122.0200	AID2546; AID2551
geminin	Homo sapiens (human)	Potency	6.5131	0.0046	11.3741	33.4983	AID624296
Glycoprotein hormones alpha chain	Homo sapiens (human)	Potency	10.0000	4.4668	8.3448	10.0000	AID624291
ATP-dependent phosphofructokinase	Trypanosoma brucei brucei TREU927	Potency	9.5662	0.0601	10.7453	37.9330	AID485367; AID504636; AID504637
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
kallikrein-5 preproprotein	Homo sapiens (human)	IC50 (µMol)	50.0000	1.3592	11.3060	50.0000	AID1431
Carbonic anhydrase 12	Homo sapiens (human)	Ki	0.0053	0.0002	1.1043	9.9000	AID587002
Carbonic anhydrase 1	Homo sapiens (human)	Ki	2.1500	0.0000	1.3726	10.0000	AID586999
Carbonic anhydrase 2	Homo sapiens (human)	Ki	0.7810	0.0000	0.7236	9.9200	AID551577; AID587000
Carbonic anhydrase	Mycobacterium tuberculosis H37Rv	Ki	0.0631	0.0120	2.7238	9.1200	AID551580
Beta-carbonic anhydrase 1	Mycobacterium tuberculosis H37Rv	Ki	0.0048	0.0048	3.3841	9.8400	AID551579
Carbonic anhydrase 9	Homo sapiens (human)	Ki	0.0580	0.0001	0.7874	9.9000	AID587001
Carbonic anhydrase	Nakaseomyces glabratus CBS 138	Ki	0.0070	0.0070	1.2174	9.1700	AID744415
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
estrous cycle	Carbonic anhydrase 12	Homo sapiens (human)
chloride ion homeostasis	Carbonic anhydrase 12	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 12	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 1	Homo sapiens (human)
morphogenesis of an epithelium	Carbonic anhydrase 2	Homo sapiens (human)
positive regulation of synaptic transmission, GABAergic	Carbonic anhydrase 2	Homo sapiens (human)
positive regulation of cellular pH reduction	Carbonic anhydrase 2	Homo sapiens (human)
angiotensin-activated signaling pathway	Carbonic anhydrase 2	Homo sapiens (human)
regulation of monoatomic anion transport	Carbonic anhydrase 2	Homo sapiens (human)
secretion	Carbonic anhydrase 2	Homo sapiens (human)
regulation of intracellular pH	Carbonic anhydrase 2	Homo sapiens (human)
neuron cellular homeostasis	Carbonic anhydrase 2	Homo sapiens (human)
positive regulation of dipeptide transmembrane transport	Carbonic anhydrase 2	Homo sapiens (human)
regulation of chloride transport	Carbonic anhydrase 2	Homo sapiens (human)
carbon dioxide transport	Carbonic anhydrase 2	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 2	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Glycoprotein hormones alpha chain	Homo sapiens (human)
positive regulation of cell population proliferation	Glycoprotein hormones alpha chain	Homo sapiens (human)
hormone-mediated signaling pathway	Glycoprotein hormones alpha chain	Homo sapiens (human)
regulation of signaling receptor activity	Glycoprotein hormones alpha chain	Homo sapiens (human)
positive regulation of steroid biosynthetic process	Glycoprotein hormones alpha chain	Homo sapiens (human)
positive regulation of cell migration	Glycoprotein hormones alpha chain	Homo sapiens (human)
thyroid gland development	Glycoprotein hormones alpha chain	Homo sapiens (human)
luteinizing hormone secretion	Glycoprotein hormones alpha chain	Homo sapiens (human)
organ growth	Glycoprotein hormones alpha chain	Homo sapiens (human)
follicle-stimulating hormone signaling pathway	Glycoprotein hormones alpha chain	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Glycoprotein hormones alpha chain	Homo sapiens (human)
negative regulation of organ growth	Glycoprotein hormones alpha chain	Homo sapiens (human)
follicle-stimulating hormone secretion	Glycoprotein hormones alpha chain	Homo sapiens (human)
thyroid hormone generation	Glycoprotein hormones alpha chain	Homo sapiens (human)
response to hypoxia	Carbonic anhydrase 9	Homo sapiens (human)
morphogenesis of an epithelium	Carbonic anhydrase 9	Homo sapiens (human)
response to xenobiotic stimulus	Carbonic anhydrase 9	Homo sapiens (human)
response to testosterone	Carbonic anhydrase 9	Homo sapiens (human)
secretion	Carbonic anhydrase 9	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 9	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
zinc ion binding	Carbonic anhydrase 12	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 12	Homo sapiens (human)
arylesterase activity	Carbonic anhydrase 1	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 1	Homo sapiens (human)
protein binding	Carbonic anhydrase 1	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 1	Homo sapiens (human)
hydro-lyase activity	Carbonic anhydrase 1	Homo sapiens (human)
cyanamide hydratase activity	Carbonic anhydrase 1	Homo sapiens (human)
arylesterase activity	Carbonic anhydrase 2	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 2	Homo sapiens (human)
protein binding	Carbonic anhydrase 2	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 2	Homo sapiens (human)
cyanamide hydratase activity	Carbonic anhydrase 2	Homo sapiens (human)
hormone activity	Glycoprotein hormones alpha chain	Homo sapiens (human)
protein binding	Glycoprotein hormones alpha chain	Homo sapiens (human)
follicle-stimulating hormone activity	Glycoprotein hormones alpha chain	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 9	Homo sapiens (human)
protein binding	Carbonic anhydrase 9	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 9	Homo sapiens (human)
molecular function activator activity	Carbonic anhydrase 9	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	Carbonic anhydrase 12	Homo sapiens (human)
membrane	Carbonic anhydrase 12	Homo sapiens (human)
basolateral plasma membrane	Carbonic anhydrase 12	Homo sapiens (human)
apical plasma membrane	Carbonic anhydrase 12	Homo sapiens (human)
plasma membrane	Carbonic anhydrase 12	Homo sapiens (human)
cytosol	Carbonic anhydrase 1	Homo sapiens (human)
extracellular exosome	Carbonic anhydrase 1	Homo sapiens (human)
cytoplasm	Carbonic anhydrase 2	Homo sapiens (human)
cytosol	Carbonic anhydrase 2	Homo sapiens (human)
plasma membrane	Carbonic anhydrase 2	Homo sapiens (human)
myelin sheath	Carbonic anhydrase 2	Homo sapiens (human)
apical part of cell	Carbonic anhydrase 2	Homo sapiens (human)
extracellular exosome	Carbonic anhydrase 2	Homo sapiens (human)
cytoplasm	Carbonic anhydrase 2	Homo sapiens (human)
plasma membrane	Carbonic anhydrase 2	Homo sapiens (human)
apical part of cell	Carbonic anhydrase 2	Homo sapiens (human)
extracellular region	Glycoprotein hormones alpha chain	Homo sapiens (human)
extracellular space	Glycoprotein hormones alpha chain	Homo sapiens (human)
Golgi lumen	Glycoprotein hormones alpha chain	Homo sapiens (human)
follicle-stimulating hormone complex	Glycoprotein hormones alpha chain	Homo sapiens (human)
pituitary gonadotropin complex	Glycoprotein hormones alpha chain	Homo sapiens (human)
extracellular space	Glycoprotein hormones alpha chain	Homo sapiens (human)
nucleolus	Carbonic anhydrase 9	Homo sapiens (human)
plasma membrane	Carbonic anhydrase 9	Homo sapiens (human)
membrane	Carbonic anhydrase 9	Homo sapiens (human)
basolateral plasma membrane	Carbonic anhydrase 9	Homo sapiens (human)
microvillus membrane	Carbonic anhydrase 9	Homo sapiens (human)
plasma membrane	Carbonic anhydrase 9	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (27)

Assay ID	Title	Year	Journal	Article
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID587000	Inhibition of human cytosolic carbonic anhydrase 2 preincubated for 15 min by CO2 hydration assay	2011	Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6	Ureido-substituted benzenesulfonamides potently inhibit carbonic anhydrase IX and show antimetastatic activity in a model of breast cancer metastasis.
AID587002	Inhibition of tumor-associated human carbonic anhydrase 12 preincubated for 15 min by CO2 hydration assay	2011	Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6	Ureido-substituted benzenesulfonamides potently inhibit carbonic anhydrase IX and show antimetastatic activity in a model of breast cancer metastasis.
AID551579	Inhibition of Mycobacterium tuberculosis recombinant beta-carbonic anhydrase Rv1284 preincubated for 15 mins by stopped-flow CO2 hydrase assay	2011	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1	Inhibition of β-carbonic anhydrases with ureido-substituted benzenesulfonamides.
AID586999	Inhibition of human cytosolic carbonic anhydrase 1 preincubated for 15 min by CO2 hydration assay	2011	Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6	Ureido-substituted benzenesulfonamides potently inhibit carbonic anhydrase IX and show antimetastatic activity in a model of breast cancer metastasis.
AID551577	Inhibition of human recombinant carbonic anhydrase 2 preincubated for 15 mins by stopped-flow CO2 hydrase assay	2011	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1	Inhibition of β-carbonic anhydrases with ureido-substituted benzenesulfonamides.
AID744415	Inhibition of recombinant full length Candida glabrata NCE103 expressed in Escherichia coli BL21 preincubated for 15 mins by stopped-flow CO2 hydrase assay	2013	Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9	Carbonic anhydrase inhibitors: inhibition of the β-class enzyme from the pathogenic yeast Candida glabrata with sulfonamides, sulfamates and sulfamides.
AID744416	Inhibition of Cryptococcus neoformans Can2 expressed in Candida albicans RH1 preincubated for 15 mins by stopped-flow CO2 hydrase assay	2013	Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9	Carbonic anhydrase inhibitors: inhibition of the β-class enzyme from the pathogenic yeast Candida glabrata with sulfonamides, sulfamates and sulfamides.
AID551583	Selectivity ratio, ratio of Ki for Mycobacterium tuberculosis recombinant beta-carbonic anhydrase Rv3273 to Ki for Candida albicans recombinant beta-carbonic anhydrase	2011	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1	Inhibition of β-carbonic anhydrases with ureido-substituted benzenesulfonamides.
AID551578	Inhibition of Candida albicans recombinant beta-carbonic anhydrase preincubated for 15 mins by stopped-flow CO2 hydrase assay	2011	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1	Inhibition of β-carbonic anhydrases with ureido-substituted benzenesulfonamides.
AID551582	Selectivity ratio, ratio of Ki for Mycobacterium tuberculosis recombinant beta-carbonic anhydrase Rv1284 to Ki for Candida albicans recombinant beta-carbonic anhydrase	2011	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1	Inhibition of β-carbonic anhydrases with ureido-substituted benzenesulfonamides.
AID587001	Inhibition of tumor-associated human carbonic anhydrase 9 preincubated for 15 min by CO2 hydration assay	2011	Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6	Ureido-substituted benzenesulfonamides potently inhibit carbonic anhydrase IX and show antimetastatic activity in a model of breast cancer metastasis.
AID551584	Selectivity ratio, ratio of Ki for Mycobacterium tuberculosis recombinant beta-carbonic anhydrase Rv3273 to Ki for human recombinant carbonic anhydrase 2	2011	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1	Inhibition of β-carbonic anhydrases with ureido-substituted benzenesulfonamides.
AID551580	Inhibition of Mycobacterium tuberculosis recombinant beta-carbonic anhydrase Rv3273 preincubated for 15 mins by stopped-flow CO2 hydrase assay	2011	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1	Inhibition of β-carbonic anhydrases with ureido-substituted benzenesulfonamides.
AID744414	Selectivity ratio of Ki for human carbonic anhydrase-2 to Ki for recombinant full length Candida glabrata NCE103	2013	Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9	Carbonic anhydrase inhibitors: inhibition of the β-class enzyme from the pathogenic yeast Candida glabrata with sulfonamides, sulfamates and sulfamides.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (12.50)	29.6817
2010's	6 (75.00)	24.3611
2020's	1 (12.50)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	8 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
acetazolamide Acetazolamide: One of the CARBONIC ANHYDRASE INHIBITORS that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337)	3.68	3	monocarboxylic acid amide; sulfonamide; thiadiazoles	anticonvulsant; diuretic; EC 4.2.1.1 (carbonic anhydrase) inhibitor
celecoxib [no description available]	2.08	1	organofluorine compound; pyrazoles; sulfonamide; toluenes	cyclooxygenase 2 inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug
dichlorphenamide Dichlorphenamide: A carbonic anhydrase inhibitor that is used in the treatment of glaucoma.. diclofenamide : A sulfonamide that is benzene-1,3-disulfonamide in which the hydrogens at positions 4 and 5 are substituted by chlorine. An oral carbonic anhydrase inhibitor, it partially suppresses the secretion (inflow) of aqueous humor in the eye and so reduces intraocular pressure. It is used for the treatment of glaucoma.	2.08	1	dichlorobenzene; sulfonamide	antiglaucoma drug; EC 4.2.1.1 (carbonic anhydrase) inhibitor; ophthalmology drug
ethoxzolamide Ethoxzolamide: A carbonic anhydrase inhibitor used as diuretic and in glaucoma. It may cause hypokalemia.. ethoxzolamide : A sulfonamide that is 1,3-benzothiazole-2-sulfonamide which is substituted by an ethoxy group at position 6. A carbonic anhydrase inhibitor, it has been used in the treatment of glaucoma, and as a diuretic.	2.08	1	aromatic ether; benzothiazoles; sulfonamide	antiglaucoma drug; diuretic; EC 4.2.1.1 (carbonic anhydrase) inhibitor
mafenide Mafenide: A sulfonamide that inhibits the enzyme CARBONIC ANHYDRASE and is used as a topical anti-bacterial agent, especially in burn therapy.	2.08	1	aromatic amine
methazolamide Methazolamide: A carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma.	2.08	1	sulfonamide; thiadiazoles
sulfanilamide [no description available]	2.48	2	substituted aniline; sulfonamide antibiotic; sulfonamide	antibacterial agent; drug allergen; EC 4.2.1.1 (carbonic anhydrase) inhibitor
sulpiride Sulpiride: A dopamine D2-receptor antagonist. It has been used therapeutically as an antidepressant, antipsychotic, and as a digestive aid. (From Merck Index, 11th ed). sulpiride : A member of the class of benzamides obtained from formal condensation between the carboxy group of 2-methoxy-5-sulfamoylbenzoic acid and the primary amino group of (1-ethylpyrrolidin-2-yl)methylamine.	2.08	1	benzamides; N-alkylpyrrolidine; sulfonamide	antidepressant; antiemetic; antipsychotic agent; dopaminergic antagonist
zonisamide Zonisamide: A benzisoxazole and sulfonamide derivative that acts as a CALCIUM CHANNEL blocker. It is used primarily as an adjunctive antiepileptic agent for the treatment of PARTIAL SEIZURES, with or without secondary generalization.. zonisamide : A 1,2-benzoxazole compound having a sulfamoylmethyl substituent at the 3-position.	2.08	1	1,2-benzoxazoles; sulfonamide	anticonvulsant; antioxidant; central nervous system drug; protective agent; T-type calcium channel blocker
4-toluenesulfonamide 4-toluenesulfonamide: RN given refers to parent cpd. toluene-4-sulfonamide : A sulfonamide that is benzenesulfonamide bearing a methyl group at position 4.	2.08	1	sulfonamide
carzenide [no description available]	2.08	1	sulfonamide
benzolamide Benzolamide: Selective renal carbonic anhydrase inhibitor. It may also be of use in certain cases of respiratory failure.	2.08	1
4-amino-6-chloro-1,3-benzenedisulfonamide 4-amino-6-chloro-1,3-benzenedisulfonamide: metabolite of hydrochlorothiazide	2.08	1	sulfonamide
brinzolamide brinzolamide: an antiglaucoma agent	2.08	1	sulfonamide; thienothiazine	antiglaucoma drug; EC 4.2.1.1 (carbonic anhydrase) inhibitor
2,4-disulfamyl-5-trifluoromethylaniline 2,4-disulfamyl-5-trifluoromethylaniline: precursor of hydroflumethiazide	2.08	1
2-aminobenzenesulfonamide [no description available]	2.08	1	benzenes; sulfonamide
5-amino-1,3,4-thiadiazole-2-sulfonamide 5-amino-1,3,4-thiadiazole-2-sulfonamide: structure in first source	2.08	1
valdecoxib [no description available]	2.08	1	isoxazoles; sulfonamide	antipyretic; antirheumatic drug; cyclooxygenase 2 inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
chlorzolamide chlorzolamide: structure	2.08	1
4-(2-aminoethyl)benzenesulfonamide [no description available]	2.08	1
n-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide: structure in first source. indisulam : A chloroindole that is 3-chloro-1H-indole substituted by a [(4-sulfamoylphenyl)sulfonyl]nitrilo group at position 7. It is a carbonic anhydrase inhibitor and a potential anti-cancer agent currently in clinical development.	2.08	1	chloroindole; organochlorine compound; sulfonamide	antineoplastic agent; EC 4.2.1.1 (carbonic anhydrase) inhibitor
u-104 SLC-0111: a carbonic anhydrase inhibitor; structure in first source	3.38	2
dorzolamide dorzolamide: topically effective ocular hypotensive carbonic anhydrase inhibitor; RN refers to mono-HCl (4S-trans)-isomer. dorzolamide : 5,6-Dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide in which hydrogens at the 4 and 6 positions are substituted by ethylamino and methyl groups, respectively (4S, trans-configuration). A carbonic anhydrase inhibitor, it is used as the hydrochloride in ophthalmic solutions to lower increased intraocular pressure in the treatment of open-angle glaucoma and ocular hypertension.	2.08	1	sulfonamide; thiophenes	antiglaucoma drug; antihypertensive agent; EC 4.2.1.1 (carbonic anhydrase) inhibitor
topiramate Topiramate: A sulfamate-substituted fructose analog that was originally identified as a hypoglycemic agent. It is used for the treatment of EPILEPSY and MIGRAINE DISORDERS, and may also promote weight loss.. topiramate : A hexose derivative that is 2,3:4,5-di-O-isopropylidene-beta-D-fructopyranose in which the hydroxy group has been converted to the corresponding sulfamate ester. It blocks voltage-dependent sodium channels and is used as an antiepileptic and for the prevention of migraine.	2.08	1	cyclic ketal; ketohexose derivative; sulfamate ester	anticonvulsant; sodium channel blocker

Condition	Relationship Strength	Studies
Innate Inflammatory Response [description not available]	2.05	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.05	1
Metastase [description not available]	2.98	1
Experimental Mammary Neoplasms [description not available]	2.98	1
Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.	2.98	1

1-(4-chlorophenyl)-3-(4-sulfamoylphenyl)urea

Cross-References

Synonyms (20)

Drug Classes (1)

Protein Targets (16)

Potency Measurements

Inhibition Measurements

Biological Processes (31)

Molecular Functions (9)

Ceullar Components (16)

Bioassays (27)

Research

Studies (8)

Market Indicators

Research Demand Index: 12.25

Study Types

1-(4-chlorophenyl)-3-(4-sulfamoylphenyl)urea

Cross-References

Synonyms (20)

Drug Classes (1)

Protein Targets (16)

Potency Measurements

Inhibition Measurements

Biological Processes (31)

Molecular Functions (9)

Ceullar Components (16)

Bioassays (27)

Research

Studies (8)

Market Indicators

Research Demand Index: 12.25

Study Types

Related Drugs (24)

Related Conditions (5)